[go: up one dir, main page]

CO2017009994A2 - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Info

Publication number
CO2017009994A2
CO2017009994A2 CONC2017/0009994A CO2017009994A CO2017009994A2 CO 2017009994 A2 CO2017009994 A2 CO 2017009994A2 CO 2017009994 A CO2017009994 A CO 2017009994A CO 2017009994 A2 CO2017009994 A2 CO 2017009994A2
Authority
CO
Colombia
Prior art keywords
sulfonimidoylpurinone
prophylaxis
derivatives
treatment
viral infections
Prior art date
Application number
CONC2017/0009994A
Other languages
English (en)
Inventor
Jianping Wang
Hongying Yun
Chungen Liang
Kun Miao
Xiufang Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2017009994A2 publication Critical patent/CO2017009994A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), en la que R1, R2 y R3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
CONC2017/0009994A 2015-05-08 2017-09-29 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas CO2017009994A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
CO2017009994A2 true CO2017009994A2 (es) 2018-02-20

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0009994A CO2017009994A2 (es) 2015-05-08 2017-09-29 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Country Status (32)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX376761B (es)
MY (1) MY182353A (es)
NZ (2) NZ735648A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI768467B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191942T1 (hr) * 2015-05-08 2020-01-10 F. Hoffmann - La Roche Ag Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije
PE20190476A1 (es) 2016-08-29 2019-04-04 Hoffmann La Roche Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
AU2017326400B2 (en) * 2016-09-13 2023-03-30 F. Hoffmann-La Roche Ag Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
KR20210136014A (ko) * 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
KR20080006004A (ko) * 2005-05-04 2008-01-15 화이자 리미티드 암 및 ｃ형 간염과 같은 바이러스 감염의 치료를 위한톨-유사 수용체 조절제인 2-아미도-6-아미노-8-옥소퓨린유도체
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
KR101787309B1 (ko) * 2008-12-09 2017-10-18 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
RS57851B1 (sr) 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
EA035110B1 (ru) 2013-03-29 2020-04-28 Янссен Сайенсиз Айрлэнд Юси Макроциклические деаза-оксипурины в качестве модуляторов tlr7
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
HRP20191942T1 (hr) * 2015-05-08 2020-01-10 F. Hoffmann - La Roche Ag Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije
PE20190476A1 (es) * 2016-08-29 2019-04-04 Hoffmann La Roche Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica

Also Published As

Publication number Publication date
IL280769B2 (en) 2023-07-01
RU2017142577A3 (es) 2019-10-31
US9708325B2 (en) 2017-07-18
MX2020010949A (es) 2022-06-16
PT3294740T (pt) 2019-10-29
PE20171620A1 (es) 2017-11-02
IL280769A (en) 2021-04-29
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
KR102690131B1 (ko) 2024-07-31
CN107580596B (zh) 2020-07-14
BR112017023959B1 (pt) 2023-05-02
HUE045906T2 (hu) 2020-01-28
US20200109144A1 (en) 2020-04-09
DK3294740T3 (da) 2019-11-04
MX393198B (es) 2025-03-19
AU2020256348B2 (en) 2022-06-16
US10399983B2 (en) 2019-09-03
IL254947A0 (en) 2017-12-31
RS59435B1 (sr) 2019-11-29
AR104528A1 (es) 2017-07-26
MX376761B (es) 2025-03-07
RU2017142577A (ru) 2019-06-10
CA2982704A1 (en) 2016-11-17
KR20180003612A (ko) 2018-01-09
UA120450C2 (uk) 2019-12-10
CN107580596A (zh) 2018-01-12
PH12017502009A1 (en) 2018-03-26
SI3294740T1 (sl) 2019-12-31
LT3294740T (lt) 2019-11-25
US20160326177A1 (en) 2016-11-10
MX2017014033A (es) 2018-03-01
US20170275286A1 (en) 2017-09-28
AU2022204666A1 (en) 2022-07-21
US11242345B2 (en) 2022-02-08
MY182353A (en) 2021-01-20
BR112017023959A2 (pt) 2018-07-17
ES2753777T3 (es) 2020-04-14
TWI706954B (zh) 2020-10-11
WO2016180695A1 (en) 2016-11-17
CA2982704C (en) 2023-10-24
AU2016260683A1 (en) 2017-10-12
SG10202108841YA (en) 2021-09-29
AU2020256348A1 (en) 2020-11-12
HRP20191942T1 (hr) 2020-01-10
HK1247925A1 (zh) 2018-10-05
IL280769B1 (en) 2023-03-01
JP6738352B2 (ja) 2020-08-12
PL3294740T3 (pl) 2020-03-31
TW201716410A (zh) 2017-05-16
TWI768467B (zh) 2022-06-21
EP3294740B1 (en) 2019-09-04
NZ775222A (en) 2024-09-27
CL2017002745A1 (es) 2018-05-18
AU2016260683B2 (en) 2020-10-29
CR20170496A (es) 2017-12-05
JP2018515509A (ja) 2018-06-14
EP3294740A1 (en) 2018-03-21
NZ735648A (en) 2023-06-30
IL254947B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2023001876A (es) Derivados de rapamicina.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY36702A (es) Piridinas sustituidas y métodos de uso
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
SV2016005317A (es) Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1